For your patients with health insurance:
Print the ZYFLO CR® patient savings card. The patient savings card provides eligible patients with a $30 co-pay* for 12 months of ZYFLO CR® therapy.

  • Promotes affordable therapy for your patients taking ZYFLO CR®

We know it’s important for your patients to take their ZYFLO CR® the way you have prescribed it, so Cornerstone Therapeutics would like to help your patients pay for their ZYFLO CR® prescriptions. Patients who use a savings card to fill 11 prescriptions in 12 months may be reimbursed for most of their co-pay costs. Print a savings card for complete enrollment instructions.*

For your patients without health insurance:
Prior authorization assistance and assistance with the cost of ZYFLO CR® prescriptions are available for your eligible patients through the Cornerstone Cares patient assistance program. Please encourage patients whose insurance does not cover ZYFLO CR® to enroll in the program for financial assistance. See the downloadable application form for complete enrollment instructions and eligibility criteria. Call toll-free at 1-888-CRTX198 for more information.
 

Patient brochure
Download a PDF of the ZYFLO CR® patient brochure.

  • Educates patients about asthma
  • Helps patients understand what to expect during treatment with ZYFLO CR®
  • Encourages patients  to take ZYFLO CR® as directed by their physician
Patient savings card and brochure

cornerstone
*See savings card for details and instructions. Subject to availability. Patients who have prescription assistance through government insurers like Medicare or Medicaid are not eligible. Other restrictions apply.

Please see Important Safety Information and full Prescribing Information.




Important Safety Information


ZYFLO CR® is a leukotriene synthesis inhibitor indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. Do not use ZYFLO CR® to treat an acute asthma attack.

ZYFLO CR® is contraindicated for patients with active liver disease or persistent hepatic function enzyme elevations  3 times the upper limit of normal. Assessment of hepatic function enzymes prior to and during ZYFLO CR® therapy should be undertaken. ZYFLO CR® is also contraindicated for patients with a history of allergic reactions to zileuton or any of the other ingredients.

The active ingredient in ZYFLO CR® increases theophylline, warfarin, and propranolol levels. Dose adjustment of these other drugs and patient monitoring may be required. ZYFLO CR® should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease. Neuropsychiatric events, including sleeping disorders and behavioral changes, may occur with ZYFLO CR®.

The most common adverse reactions (>5%) include: sinusitis, nausea, and pharyngolaryngeal pain.